Condition (MeSH)
Arthropathy, Neurogenic
ClinicalTrials.gov lists 7 trials for Arthropathy, Neurogenic or a narrower condition beneath it. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
7 of the 7 trials are tagged with Arthropathy, Neurogenic itself; the rest are tagged with a narrower condition beneath it.
When did Arthropathy, Neurogenic trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2/3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2005 | 1 |
| 2003 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Arthropathy, Neurogenic trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2/3 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Arthropathy, Neurogenic trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 5 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Arthropathy, Neurogenic trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 1 |
Which serious adverse events do Arthropathy, Neurogenic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Headache | 5 | 1 |
| Lung infection | 2 | 1 |
| Meningitis | 2 | 1 |
| Pain | 2 | 1 |
| Acute Tonsillitis/tooth abscess | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Arthropathy, Neurogenic? (40)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). | Diabetes/metabolism research and reviews | 2024 | Yes |
| Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus. | PloS one | 2021 | Yes |
| Clinical insights into Charcot foot. | Best practice & research. Clinical rheumatology | 2020 | Yes |
| Hybrid Fixation for Ankle Fusion in Diabetic Charcot Arthropathy. | Foot & ankle international | 2018 | Yes |
| Genotype-phenotype investigation of 35 patients from 11 unrelated families with camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome. | Molecular genetics & genomic medicine | 2018 | Yes |
Showing 5 of 40 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.